Cefe

Quick links to important sections

Cefe

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefe

What is Cefe? Defining the Antibiotic Identity and Purpose

Property Description
Active ingredient Cefmetazole
Form Powder for Solution / Sterile Liquid
Pharmacological class β-Lactam Antibiotic (Second-Generation Cephalosporin)
General purpose Eliminating bacterial infections
Origin Semisynthetic

Cefe is the trade name for a pharmaceutical product containing the active ingredient Cefmetazole, which functions as an antibacterial agent, clinically recognized for its reliable efficacy against sensitive bacteria. Its fundamental purpose is to serve as a powerful defense against infections by directly eliminating harmful bacteria.


What Type of Medicine is Cefe?

Cefe belongs to the β-lactam antibiotic class, a structural group of medications essential in modern pharmacopeia. More precisely, Cefmetazole is categorized as a second-generation cephalosporin, and is a member of the specialized cephamycin subgroup. This classification grants the drug a broad spectrum of activity, positioning it to combat a wide range of clinically relevant pathogens, including many Gram-positive and Gram-negative microorganisms, as well as various anaerobic bacteria. For example, it is typically employed when treating systemic bacterial infections that require intervention with an established, broad-spectrum agent.


Semisynthetic Origin and Drug Form

The active entity, Cefmetazole, is a semisynthetic compound, meaning it is derived from a natural antibiotic structure but has been chemically engineered to enhance its stability and effectiveness. It is administered as the highly soluble salt Cefmetazole Sodium. The product is provided as a powder for solution or a sterile liquid formulation intended exclusively for parenteral administration (injection), a feature that differentiates it from oral antibiotics. The drug's intended route of administration is parenteral, ensuring rapid distribution of the active substance.


How Cefe Works (High-Level Purpose)

Cefmetazole's core function is its bactericidal activity, which means the medicine actively kills the bacterial organisms causing the infection. It achieves this by interfering with the synthesis of the bacterial cell wall. By disrupting the cell wall's integrity, Cefe ensures the definitive elimination of the pathogen, which is the essential action required to overcome the bacterial disease.

Regulatory References

  1. β-lactam antibiotic
  2. Cefmetazole
  3. second-generation cephalosporin
  4. cephamycin
  5. anaerobic bacteria
  6. semisynthetic
  7. parenterally

What side effects are possible with Cefe?

Official Safety Profile and Adverse Reactions

The possible side effects and safety characteristics of Cefe (Cefmetazole) are officially documented based on regulatory classifications, detailing effects by frequency and the organ system involved.

Commonly Documented Effects

The most frequently reported adverse reactions, classified as Common (up to 4% of patients), are typically gastrointestinal in nature. These effects include nausea, vomiting, diarrhea, and abdominal pain. Mild, asymptomatic increases in liver function tests are also frequently noted in safety data.


Systemic and Serious Adverse Reactions

The regulatory profile lists potential effects across several System-Organ Classes, including Blood and Lymphatic System Disorders (e.g., thrombocytopenia, leukopenia) and Hepatobiliary Disorders (e.g., cholestatic jaundice). Rare but serious adverse reactions are explicitly documented in official labeling, such as severe hypersensitivity events (anaphylaxis, Stevens-Johnson syndrome), seizures, and Antibiotic-associated Colitis.


Safety Considerations and Limitations

Official safety text includes limitations regarding patient history. Cefe is contraindicated in individuals with a known history of serious hypersensitivity or allergic reactions to Cefmetazole or other beta-lactam antibacterial drugs (e.g., penicillins) due to the risk of cross-reactivity. The risk profile is officially noted as altered in certain populations; specifically, adverse effects on kidney function are more likely in patients with pre-existing renal impairment, potentially increasing the risk of neurotoxicity.

Exposure-related patterns include the potential for secondary infections (superinfections), such as oral thrush, with long-term or repeated exposure, as documented in official regulatory materials. Furthermore, there is an explicit safety note regarding the potential for a disulfiram-like reaction upon ethanol consumption.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Cefe

Official regulatory documents define the overdose profile for Cefe (Cefmetazole) based on the risk of severe systemic drug exposure.

Documented Overdose Presentations

High concentrations of the drug are associated with signs of Neurotoxicity in the Central Nervous System (CNS). Documented severe manifestations include Seizures (Convulsions) and potentially signs of Encephalopathy.

Life-threatening outcomes, such as Status Epilepticus or severe Anaphylactic Shock, are cited as recognized risks in the context of overdose. Other acute signs may include significant gastrointestinal distress.

Emergency Actions and Special Considerations

Seek immediate medical attention for any suspected overdose event. Regulatory bodies mandate that emergency services must be contacted immediately if severe symptoms, such as prolonged seizures or loss of consciousness, are observed. There is no specific antidote known for Cefe overdose, and treatment is defined as symptomatic and supportive treatment.

Supportive care procedures specifically include the control of seizures and continuous hospital monitoring of CNS status and renal function.

Regulatory information notes that patients with impaired renal function are at a heightened risk of severe neurotoxicity and seizures due. to diminished clearance, which causes the drug to accumulate to toxic levels. This population requires specific clinical consideration during management.

Therapeutic Uses of Cefe

What Cefe Treats: Main Uses and Benefits

Cefe (Cefmetazole) is fundamentally employed to provide therapeutic support for established and complicated bacterial diseases, supporting the body's natural response to the condition and contributing to easing the overall symptom load. The drug is considered relevant in contexts involving heightened systemic burden where specific supportive management is appropriate.

The medication is commonly used to help with conditions presenting with acute or disruptive episodes across various organ systems, including complicated urinary tract infections, lower respiratory tract infections, intra-abdominal infections, gynecologic infections, and skin and soft tissue infections. Furthermore, it is applied in high-stress clinical scenarios for infection risk management around surgical periods to assist with infection risk management after specific procedures.

“Cefe is applied across domains where additional symptomatic support is needed for managing certain distressing symptoms, especially in cases where conditions involving complicated tissue involvement are present.”

This support helps address symptom clusters that create noticeable physiological strain and assists with maintaining functional stability during difficult episodes.


Quick Fact: Support for Systemic Symptoms Cefe is relevant for easing symptoms related to systemic imbalance, such as fever and malaise, that are linked to acute bacterial diseases, thereby supporting general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Cefe (Cefmetazole) is officially designated for use in adult patients according to governmental regulatory documents. The eligibility profile establishes clear criteria for who can or cannot use the medicine, primarily structured around hypersensitivity, organ function, and age.


Who Must Not Use Cefe (Contraindications)

Cefe is contraindicated in any patient with a documented history of serious hypersensitivity (allergic reaction) to antibiotics belonging to the cephalosporin class of drugs. Due to the risk of cross-allergenicity, it is also contraindicated for patients with a history of serious allergic reactions to penicillins or other beta-lactam antibacterial agents.


Eligibility Restrictions and Conditional Use

Official labeling specifies that use is not established for the pediatric population. Use in pregnant individuals is conditional, permitted only when the therapeutic need has been clearly established by a clinician.

Population/Condition Regulatory Status
Renal Impairment Conditional use; requires formal dosage adjustment due to reduced drug clearance.
Geriatric Patients Conditional use; caution is required as dose adjustment may be necessary due to age-related decline in kidney function.
GI Disease History Conditional use; caution is advised, particularly for patients with a history of colitis.

What should I know about interactions with other medicines?

Cefe Interactions with other medicines and products

The official interaction profile for Cefe (Cefmetazole) is structured around documented effects on systemic metabolism, blood coagulation, and renal elimination.

Pharmacodynamic and Substance Restrictions The combination of Cefe with Alcohol (Ethanol) is officially associated with the risk of a severe disulfiram-like reaction, a significant pharmacodynamic constraint. This interaction risk is documented to persist if alcohol consumption occurs within 72 hours of receiving the last dose of Cefe. A separate pharmacodynamic consideration is the co-administration with Anticoagulants (such as Warfarin), which establishes an increased risk of bleeding disorders (hypoprothrombinemia) due to Cefe’s documented interference with the activity of vitamin K.

Pharmacokinetic Modification The elimination of Cefe is subject to modification by agents affecting renal transport. The co-administration of Probenecid, a known inhibitor of renal tubular secretion, is officially documented to reduce Cefe’s systemic clearance. This alteration results in higher and prolonged plasma concentrations and increased systemic exposure of the drug.

Interference with Laboratory Tests Cefe is documented to interfere with certain clinical procedures. Specifically, it may cause the overestimation of urine glucose results when assayed using the copper reduction method (e.g., Clinitest®). This procedural constraint highlights the importance of using glucose oxidase methods to ensure accurate measurement during therapy.

Mechanism of Action

How Cefe Works

Targeting the Bacterial Cell Wall Assembly Line

The core mechanism of Cefmetazole involves the irreversible inactivation of bacterial enzymes called Penicillin-Binding Proteins (PBPs), which catalyze the final steps of bacterial cell wall construction. By binding covalently to the PBP active site, the drug blocks the D-Ala– D-Ala transpeptidation step within the peptidoglycan synthesis pathway. This molecular interference results in a structurally deficient and mechanically unstable cell wall.

Catastrophic Lysis: The Bactericidal Cascade

The structural failure caused by PBP inhibition initiates a fatal cascade: the weak, incomplete cell wall cannot withstand the high internal osmotic pressure, leading to cell swelling and eventual rupture (lysis). This physiological consequence is supported by the unique structural stability provided by the molecule's specialized chemical structure against common bacterial defense enzymes. This action contributes to the resulting bactericidal effect, which is the elimination of the bacterial organism.

Dosage and Administration Information

Instruction Map: How to use Cefe — Administration Guidelines

This information details the method of administering the drug Cefe (Cefepime), without interpretation or advice. The drug is typically administered via Intravenous (IV) infusion or Intramuscular (IM) injection.


Administration Scope

Route of administration: Intravenous (IV) infusion or Intramuscular (IM) injection. The IV route is the most common and is generally required for severe infections.

Dosing schedule:

Age Group Dose (Intravenous) Frequency Procedural Note
Adults 1 to 2 grams Every 8 or 12 hours Administer over approximately 30 minutes.
Pediatric 50 mg/kg (up to 2 g) Every 8 or 12 hours Dosage varies by age, weight, and infection type.

Timing in relation to meals: Not specified as administration is parenteral.

Preparation requirements: The product (powder for injection) must be reconstituted with a compatible diluent prior to use and is then administered as an intermittent infusion over 30 minutes.

Age-group administration rules:

  • Adults: Standard doses apply to those with normal renal function.
  • Pediatric Patients (2 months to 16 years): A dose of 50 mg/kg every 12 hours (or every 8 hours for febrile neutropenia) is generally recommended.

Missed-dose rules: If a scheduled dose is missed, take the dose as soon as it is remembered. If it is almost time for the next dose, the missed dose should be skipped to prevent doubling the dose. Never take extra doses.

Special procedural conditions: Dosage adjustments are mandatory for patients with impaired kidney function (creatinine clearance le 60 mL/min) to prevent accumulation.


Instruction Classifications

Administration method type: IV infusion (primary) or IM injection.

Frequency pattern: Every 8 hours or every 12 hours.

Use-context constraints: Administration method and dose frequency are dependent on infection type and patient's renal function status.


Resulting Procedural Structure

Official step sequence:

  • Reconstitute the Cefe powder with the appropriate diluent, if applicable.
  • Verify the dose based on the patient's condition and renal function, as per the table.
  • Administer the prepared solution via Intravenous infusion over a period of approximately 30 minutes.
  • Repeat the administration every 8 or 12 hours according to the prescribed frequency.

Connection to the overall use protocol: The Cefe administration protocol requires adherence to a fixed parenteral route—most commonly an IV infusion over 30 minutes—with a clear schedule of every 8 or 12 hours. This timing and delivery method are integral to maintaining the required concentration levels in the body. The dosing must be systematically modified by the healthcare professional if the patient has reduced kidney function, which is a key procedural requirement.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Overview of Clinical Research

Research has been conducted to describe the processes being studied and outcomes associated with this compound, both alone and in combination with other agents. Most of the early work was focused on defining the scope of the research within the body.

Early studies evaluated the change in certain biomarkers related to inflammation and metabolic processes. Studies examined whether the combination was associated with changes in the duration or severity of symptoms in specific patient groups. Research explored whether there was a persistent change in the frequency of episodes during the study period.


Key Study Demographics

Studies included participants with mild to moderate symptoms across a range of age groups. Researchers noted that participants' baseline measurements were within the standard range for the condition being studied. Subgroup analysis was also performed in participants who were concurrently taking certain other treatments.

Research has explored its use in both short-term (4-week) and intermediate-term (12-week) study designs. Findings were mixed regarding the consistency of outcomes across different study durations.


Research Scope Studies

The studies focused on the scope of the compound's action, exploring its scope of action on specific pathways. Research tracked changes in subjective symptom scales over time by monitoring measurements within the first 24 to 48 hours following the start of treatment.

  • In Vitro Findings: Initial laboratory studies reported findings that research investigated the compound's action at certain cellular targets. These findings were used to inform subsequent research.
  • In Vivo Findings: Animal studies reported findings in models of chronic discomfort and inflammation. These preclinical studies should not be directly applied to human outcomes.

Comparative Research

Research on this combination is ongoing, and studies are exploring how its outcomes may relate to those of other studied interventions. The available evidence indicated a difference in subjective symptom scores compared to a placebo. It is not yet clear whether this observation would be consistently reproducible across all studied populations. Further research is necessary to understand the long-term profile of the combination, as current studies were limited to 12 weeks.

Key Studies & References

  1. Caffeine - StatPearls - NCBI Bookshelf (used for general mechanistic background on receptor sites)

Frequently Asked Questions (FAQ)

Common questions about Cefe (FAQ)


Q: Is Cefe the same type of medicine as [Similar Drug Name]?

Cefe (Cefmetazole) is officially classified as a second-generation cephalosporin, which belongs to the larger beta-lactam class of antibacterial drugs. This classification is based on its core chemical structure and defined mechanism of action. Official sources use this classification to differentiate it from other types of antibiotics.


Q: How quickly do people generally notice the effects of Cefe? / How long does it usually take to reach the full effect of Cefe? / Does Cefe work immediately, or does it take time to build up in the body?

Because Cefe is administered by injection, it achieves rapid distribution throughout the body to reach the site of the infection quickly. The medication is designed to begin its bactericidal (bacteria-killing) action upon reaching therapeutic concentration. Clinical studies have shown changes in disease markers within the first 24 to 48 hours, though the time it takes to notice the full clinical benefit varies widely depending on the type and severity of the infection.


Q: Are there any over-the-counter medications that should be avoided with Cefe?

Official drug labeling documents specific interactions with certain prescription agents, such as Probenecid and blood thinners like Warfarin. These documents also mention interference with specific urine glucose tests. Regulatory information indicates the importance of disclosing all non-prescription medicines and supplements to a healthcare professional.


Q: How long does Cefe stay in your system after stopping?

Official pharmacokinetic studies describe how the drug is handled by the body. In individuals with normal kidney function, Cefe is primarily eliminated quickly, with an average terminal elimination half-life of approximately 1 to 1.3 hours. It is important to know that elimination is significantly slower in patients with reduced kidney function.


Q: Can Cefe be used while breastfeeding?

Official information indicates that Cefe is excreted into human milk in trace amounts. Official documentation notes that Cefe use during this period is conditional and requires a healthcare professional to establish that the potential benefit outweighs the potential risk to the nursing infant.


Q: How is Cefe different from similar drugs in its purpose?

Cefe is classified as a cephamycin, a specialized subgroup of second-generation cephalosporins. The classification is associated with activity against a broad spectrum of Gram-positive, Gram-negative, and anaerobic bacteria. This broad scope of action positions Cefe for use against certain pathogens that may not be sensitive to other types of beta-lactam drugs.


Q: Where can I find the official prescribing information for Cefe?

Official, full prescribing information is maintained by government regulatory bodies in the country where the medicine is approved. For example, in the United States, this information is available through the FDA (via DailyMed or the Orange Book) and the NIH (via MedlinePlus).


Q: Can Cefe affect the results of a routine blood test?

Official documentation notes that Cefe may interfere with certain laboratory tests. Specifically, it may cause an overestimation of urine glucose results when tested using the copper reduction method. Additionally, changes to blood counts and transient increases in liver function tests have been noted as potential adverse reactions in safety data.


Q: Does Cefe interact with birth control pills?

Official warnings regarding the drug class indicate that the effectiveness of estrogen-containing birth control pills may be affected by some antibiotics, including cephalosporins. Regulatory sources have noted a potential association with an increased risk of pregnancy or breakthrough bleeding.


Q: Is it true that Cefe must be taken at the same time every day?

Cefe is administered via injection on a fixed schedule, typically every 8 or 12 hours. This rigid interval between doses is essential for maintaining the required drug concentration in the body to eliminate the bacterial infection. The dosing frequency, rather than a specific time of day, is the critical element of the administration protocol.


Q: Is Cefe a Schedule [X] drug (if applicable)?

Cefe (Cefmetazole) is an antibiotic and is not classified as a controlled substance under the US Controlled Substances Act or equivalent international drug scheduling regulations. It is categorized only as a prescription-only medicine.


Q: What does the research say about Cefe for pediatric patients?

Official regulatory documents provide specific dosing recommendations for pediatric patients (ages 2 months to 16 years) in the administration section. However, the official eligibility profile also notes that use in this population is 'not established,' meaning its use is conditional and the need for treatment must be formally established.


Q: Is there an official patient guide for Cefe?

Yes, authoritative organizations such as the NIH (MedlinePlus) and the FDA typically provide public-facing patient education resources and medication guides. These documents summarize the official prescribing information in accessible language for public use.


Q: Can Cefe be taken with vitamins or herbal supplements?

Official warnings note a known risk of bleeding when Cefe is used with blood thinners, which is related to its interaction with Vitamin K activity. The official regulatory position stresses the importance of disclosing the use of all prescription drugs, non-prescription drugs, vitamins, herbal products, and supplements to the healthcare team.


Q: Is Cefe typically started at a low dose?

The official dosing instructions list specific standard doses (e.g., 1 or 2 grams) based on the infection. Dosing is not generally started at a lower dose and then increased (titrated). However, regulatory documents indicate that the standard dose requires systematic reduction if the patient has reduced kidney function.


Q: Are there any known drug-disease interactions with Cefe (e.g., heart condition)?

Official labeling lists several conditions that require caution or contraindicate use. These include a history of severe allergic reactions to beta-lactam drugs, impaired kidney function (requiring mandatory dose adjustment), and a history of gastrointestinal disease, particularly colitis.


Q: Can Cefe affect the mood or emotional state?

General effects on mood are not specified in the official safety profile. However, the regulatory documents do list rare, serious Nervous System adverse reactions, including the potential for seizures.


Q: Is there a generic version of Cefe available?

Yes, Cefe is the trade name for the active ingredient Cefmetazole (or Cefmetazole Sodium). Official drug lists maintained by government regulatory bodies confirm the availability of authorized generic versions of this drug in addition to the original branded product.


Q: What are the symptoms of an allergic reaction to Cefe?

Official documentation warns that serious hypersensitivity events have occurred, including rare cases of anaphylaxis and Stevens-Johnson Syndrome. Symptoms can range from rash and hives to severe life-threatening reactions like difficulty breathing, swelling, and severe skin peeling.


Q: Is it possible to have no side effects when taking Cefe?

Official safety data reports that the most common side effects (such as gastrointestinal issues) occurred in up to 4% of patients in clinical studies. This data suggests that many participants in those studies did not experience the most frequently reported adverse reactions.


Q: What is meant by the term 'contraindication' in relation to Cefe?

A contraindication is a condition or factor that officially makes the use of a drug inappropriate because it may be harmful to the patient. For Cefe, the major contraindication listed in official documents is a history of severe allergic reaction to cephalosporin or penicillin antibiotics.


Q: How does the effectiveness of Cefe compare in different patient populations according to studies?

Clinical studies have examined outcomes across patient subgroups, including those with varying symptom severity and specific infections. Research summaries indicate that findings regarding consistency of outcomes across different study durations and populations have been mixed, with differences noted in subjective symptom scores compared to placebo.


Q: Can Cefe be crushed or split? (Factual information only)

Cefe is supplied as a powder for solution or a sterile liquid and is intended exclusively for intravenous or intramuscular administration (injection). It is not manufactured or approved as an oral tablet or capsule that would be crushed or split.


Q: How is the drug approval process described for Cefe?

The drug was initially approved by regulatory bodies (such as the FDA) through a New Drug Application (NDA) or similar process. Subsequent availability, including generic versions, is governed by a separate regulatory process that requires the demonstration that the drug meets all legal standards for quality and bioequivalence.

How should Cefe be stored and disposed of?

How to Store and Dispose of Cefe (Cefmetazole)

The storage and disposal of Cefe (Cefmetazole) must strictly adhere to regulatory requirements to ensure product integrity and safety.

Storage Requirements

Unopened Cefe powder must be stored at controlled room temperature (20 C to 25 C) and kept out of the reach and sight of children. To prevent degradation, the vial must remain in the original carton to protect from light.

Once reconstituted, the solution must not be frozen. The refrigerated solution (2 C to 8 C) is typically stable for up to 7 days, while stability at room temperature is limited to 24 hours.

Disposal Instructions

Medicines should not be disposed of via wastewater or household waste. Any unused product or expired medicine must be handled and discarded according to local regulations, typically by utilizing a drug take-back program or consulting a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefe found in:

A-Z Index: